×
News Home

Do Analysts Expect Arena Pharmaceuticals, Inc. (ARNA) Stock to Rise After It Has Risen 0.19% in a Month?

Thursday, January 20, 2022 03:29 PM | InvestorsObserver Analysts
Do Analysts Expect Arena Pharmaceuticals, Inc. (ARNA) Stock to Rise After It Has Risen 0.19% in a Month?

Wall Street is positive on Arena Pharmaceuticals, Inc. (ARNA). On average, analysts give ARNA a Buy rating. The average price target is $96.375, which means analysts expect the stock to add by 5.81% over the next twelve months. That average ranking earns ARNA an Analyst Rating of 18, which is better than 18% of stocks based on data compiled by InvestorsObserver.

Overall Score - 3.6
Wall Street analysts are rating ARNA a Buy today. Find out what this means to you and get the rest of the rankings on ARNA!

Why are Analyst Ratings Important?

Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve. InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.

What's Happening With Arena Pharmaceuticals, Inc. Stock Today?

Arena Pharmaceuticals, Inc. (ARNA) stock is trading at $91.08 as of 3:28 PM on Thursday, Jan 20, a decline of -$0.43, or -0.47% from the previous closing price of $91.51. The stock has traded between $91.02 and $91.98 so far today. Volume today is less active than usual. So far 624,059 shares have traded compared to average volume of 2,119,425 shares. Click Here to get the full Stock Report for Arena Pharmaceuticals, Inc. stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App